EPHB1 and cancer: Higher values of ADH4 (targeted by nitrefazole), EDAR, EPHB1 (targeted by cancer drug vandetanib), ERAP1 (targeted by cancer drug tosedostat), and FCG2A associated with lower HF risk, while higher values of APOC3, CAN2 (targeted by amyloidosis drugs bortezomib and carfilzomib), and GRAB associated with higher HF risk (Fig. 4, Table S7).